PMID- 36408243 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221122 IS - 1663-9812 (Print) IS - 1663-9812 (Electronic) IS - 1663-9812 (Linking) VI - 13 DP - 2022 TI - The efficiency and safety of Shengxuening tablet on treating and preventing iron deficiency anemia: A systematic review and meta-analysis. PG - 1029641 LID - 10.3389/fphar.2022.1029641 [doi] LID - 1029641 AB - Background: Iron deficiency anemia (IDA) is a public health problem worldwide. Shengxuening Tablet (SXN) has been used for the treatment of various types of anemia, attaining high efficacy. Objective: To evaluate the safety of SXN as well as its preventive and therapeutic efficacy against IDA across different population groups. Methods: PubMed, Embase, Web of Science, the Cochrane Library, the China Knowledge Network, the China Biomedical Literature Database, the Wanfang Data Knowledge Service Platform, and the China Science and Technology Journal Database was searched for relevant clinical trials through June 2022 and a systematic review and meta-analysis of the identified studies was undertaken. Results: A total of 39 trials involving 4,562 cases were included in the meta-analysis. The total efficiency of SXN was superior than the control group in improving red blood cell (RBC) count [SMD = 1.31, 95% CI (0.7, 1.91), p < 0.0001], hemoglobin (Hb) [SMD = 1.11, 95% CI (0.75, 1.46), p < 0.00001], mean corpuscular volume (MCV) [SMD = 0.5, 95% CI (0.33, 0.68), p < 0.00001], total serum iron (SI) levels [SMD = 1.87, 95% CI (1.3, 2.44), p < 0.00001], and transferrin saturation (TSAT) levels [SMD = 2.07, 95% CI (1.86, 2.27), p < 0.00001]. Besides, the total effects of SXN to improve mean corpuscular hemoglobin (MCH) [SMD = 0.12, 95% CI (-0.16, 0.4), p = 0.41], mean corpuscular hemoglobin concentration (MCHC) [SMD = 0.03, 95% CI (-0.18, 0.24), p = 0.77], hematocrit (HCT) [SMD = 0.65, 95% CI (-0.25, 1.55), p = 0.16], and serum ferritin (SF) levels [SMD = 0.59, 95% CI (-0.67, 1.85), p = 0.36] and reduce the total iron binding capacity (TIBC) [SMD = 0.34, 95% CI (-0.07, 0.74), p = 0.1] was comparable to that of iron supplementation. SXN significantly raised the total effective rates of IDA [risk ratio (RR) = 1.06, 95% CI (1.02, 1.09), p = 0.0005] and was associated with fewer adverse events [RR = 0.24, 95% CI (0.18, 0.31), p < 0.00001], fewer adverse pregnancy outcomes [RR = 0.34, 95% CI (0.2, 0.57), p < 0.0001], and lower anemia recurrence rates during pregnancy [RR = 0.29, 95% CI (0.1, 0.84), p = 0.02]. Regarding prevention, the effects of SXN to maintain the RBC count, Hb level and other IDA-related parameters were comparable to that of control group and SXN reduced the risk of IDA incidence during pregnancy. Conclusion: SXN demonstrated promising efficacy in the treatment and prevention of IDA and outperformed routine iron formulations in terms of safety, thus rendering SXN a reliable treatment option for IDA. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier: CRD42022353247. CI - Copyright (c) 2022 Zhang, Lv, Sun, Li, Wang, Niu, Zhao, Zhang, Wang, Liu and Hu. FAU - Zhang, Yanyu AU - Zhang Y AD - Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China. AD - Graduate School, China Academy of Chinese Medical Sciences, Beijing, China. FAU - Lv, Yan AU - Lv Y AD - Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China. FAU - Sun, Yan AU - Sun Y AD - Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China. AD - Graduate School, Beijing University of Chinese Medicine, Beijing, China. FAU - Li, Yumeng AU - Li Y AD - Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China. AD - Graduate School, China Academy of Chinese Medical Sciences, Beijing, China. FAU - Wang, Dehao AU - Wang D AD - Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China. AD - Graduate School, Beijing University of Chinese Medicine, Beijing, China. FAU - Niu, Jicong AU - Niu J AD - Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China. AD - Graduate School, China Academy of Chinese Medical Sciences, Beijing, China. FAU - Zhao, Pei AU - Zhao P AD - Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China. AD - Graduate School, Beijing University of Chinese Medicine, Beijing, China. FAU - Zhang, Mei AU - Zhang M AD - Department of Hematology, Beijing Longfu Hospital, Beijing, China. FAU - Wang, Mingjing AU - Wang M AD - Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China. FAU - Liu, Weiyi AU - Liu W AD - Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China. FAU - Hu, Xiaomei AU - Hu X AD - Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China. LA - eng PT - Systematic Review DEP - 20221103 PL - Switzerland TA - Front Pharmacol JT - Frontiers in pharmacology JID - 101548923 PMC - PMC9669986 OTO - NOTNLM OT - Shengxuening tablet OT - iron deficiency anemia OT - meta-analysis OT - random controlled trials OT - systematic review COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/11/22 06:00 MHDA- 2022/11/22 06:01 PMCR- 2022/11/03 CRDT- 2022/11/21 04:49 PHST- 2022/08/27 00:00 [received] PHST- 2022/10/14 00:00 [accepted] PHST- 2022/11/21 04:49 [entrez] PHST- 2022/11/22 06:00 [pubmed] PHST- 2022/11/22 06:01 [medline] PHST- 2022/11/03 00:00 [pmc-release] AID - 1029641 [pii] AID - 10.3389/fphar.2022.1029641 [doi] PST - epublish SO - Front Pharmacol. 2022 Nov 3;13:1029641. doi: 10.3389/fphar.2022.1029641. eCollection 2022.